ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2140 • ACR Convergence 2022

    Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast

    Philip J Mease1, Dafna Gladman2, Georg Schett3, Maria Paris4, Sue Cheng5, Sven Richter5, Lichen Teng5 and Arthur Kavanaugh6, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 3Universitätsklinikum Erlangen, Erlangen, Germany, 4Amgen Inc., Westfield, NJ, 5Amgen, Inc., Thousand Oaks, CA, 6University of California San Diego, La Jolla, CA

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic systemic inflammatory musculoskeletal disease. The potential relationship between PsA therapies and specific safety events such as major adverse…
  • Abstract Number: 2144 • ACR Convergence 2022

    JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis

    Maria Gabriella Raimondo1, Charles Gwellem Anchang1, Hannah Labinsky2, Mina Saad Aziz Saad1, Simon Rauber1, Mario Vogg1, Eleni Kampylafka1, Johannes Knitza1, Alina Soare1, Georg Schett3 and Andreas Ramming1, 1Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Janus Kinase (JAK)/Signal Transducers and Activator of Transcription (STAT) is not only involved in IL23- signaling, but rather implemented into a broad range of…
  • Abstract Number: 2145 • ACR Convergence 2022

    Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials

    Lars Erik1, Kim Papp2, Douglas White3, Cecilia Asnal4, Wenjing Lu5, Ahmed Soliman5, Byron Padilla6, Michael Chen5 and Andrew Ostor7, 1Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, 2K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, 3Rheumatology Department, Waikato Hospital, and Waikato Clinical School, University of Auckland, Hamilton, New Zealand, 4Hospital Alemán, Buenos Aires, Argentina, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Inc., Waukegan, IL, 7Cabrini Hospital, Monash University & Emeritus Research, Melbourne, Australia

    Background/Purpose: PsA is a chronic, systemic inflammatory disease with a variety of clinical manifestations including arthritis, enthesitis, and dactylitis and is associated with skin and…
  • Abstract Number: 2139 • ACR Convergence 2022

    Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

    Iain B McInnes1, Philipp Sewerin2, Mohamed Sharaf3, Michela Efficace4, May Shawi5, Michelle Perate6, Miriam Zimmermann7 and Laura Coates8, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Janssen Cilag SpA, Imperia, Italy, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6Janssen Scientific Affairs, LLC, Horsham, PA, 7Janssen Scientific Affairs, LLC, Zug, Switzerland, 8Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
  • Abstract Number: 2034 • ACR Convergence 2022

    What Is the Best Initial Screening for Suspected Sjögren’s Disease?

    Katja Perdan Pirkmajer, Jelka Kramarič, matija Tomšič and Alojzija Hocevar, University Medical Centre Ljubljana, Ljubljana, Slovenia

    Background/Purpose: During the COVID-19 pandemic the routine diagnostic procedure in Sjögren's disease (SS) was highly hampered. The aim of our study was to determine in…
  • Abstract Number: 2086 • ACR Convergence 2022

    Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus

    Ann E Clarke1, Manuel Ugarte-Gil2, Megan Barber3, John Hanly4, Murray Urowitz5, Yvan St. Pierre6, Caroline Gordon7, Sang-Cheol Bae8, Juanita Romero-Diaz9, Jorge Sanchez-Guerrero10, Sasha Bernatsky6, Daniel Wallace11, David Isenberg12, Anisur Rahman13, Joan Merrill14, Paul R Fortin15, Dafna Gladman16, Ian N. Bruce17, Michelle Petri18, Ellen M. Ginzler19, Mary Anne Dooley20, Rosalind Ramsey-Goldman21, Susan Manzi22, Andreas Jönsen23, Ronald van Vollenhoven24, Cynthia Aranow25, Meggan Mackay25, Guillermo Ruiz-Irastorza26, S. Sam Lim27, Murat Inanc28, Kenneth Kalunian29, Soren Jacobsen30, Christine Peschken31, Diane Kamen32, Anca Askanase33, Bernardo Pons-Estel34 and Graciela Alarcón35, 1University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 2Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 3Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 4Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, 5University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 6Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 7Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 8Hanyang University Medical Center, Seoul, Republic of Korea, 9Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, 10Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, 11Cedars-Sinai Medical Center, Los Angeles, CA, 12University College London, London, United Kingdom, 13Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, 16Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 17Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 18Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 19SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 20Raleigh Neurology Associates, Chapel Hill, NC, 21Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, 22Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, 23Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, 24Amsterdam University Medical Centers, Amsterdam, Netherlands, 25Feinstein Institutes for Medical Research, Manhasset, NY, 26Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, 27Emory University, Atlanta, GA, 28Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, 29University of California San Diego, La Jolla, CA, 30Rigshospitalet, Copenhagen, Denmark, 31University of Manitoba, Winnipeg, MB, Canada, 32Medical University of South Carolina, Charleston, SC, 33Columbia University Medical Center, New York, NY, 34Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 35The University of Alabama at Birmingham, Oakland

    Background/Purpose: Remission and low disease activity (LDA) are associated with decreased flares, damage, and mortality. However, little is known about the impact of disease activity…
  • Abstract Number: 2131 • ACR Convergence 2022

    Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis

    Alen Zabotti1, Sarah Ohrndorf2, William Tillett3, Marlies Neuhold4, Michel van Speybroeck5, Elke Theander6, Christine Contré7, Mohamed Sharaf8, May Shawi9, Michelle Perate10, Alexa Kollmeier11 and Pascal Richette12, 1Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 4Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, 5Janssen Pharmaceutica, Beerse, Belgium, 6Janssen Cilag, Lund, Sweden, 7Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, 8Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 9Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 10Janssen Scientific Affairs, LLC, Horsham, PA, 11Janssen-Cilag, Research & Development, LLC, San Diego, CA, 12Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France

    Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19 subunit, demonstrated joint and skin efficacy in patients with active psoriatic arthritis (PsA) in the…
  • Abstract Number: 2030 • ACR Convergence 2022

    Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome

    Jonathan Hubbard1, Kim Campbell1, Kathy Sivils1, Robert Hoffman1, Kim Hung Lo1, Jocelyn Leu1, Sophia Liva1, Qing Zuraw1, Anne Stevens1, Leona Ling2, Keith Karcher3, Sindhu Ramchandren3, Hong Sun3, Hal Scofield4, Daniel Wallace5 and Raphaèle Seror6, 1Janssen Research and Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, Cambridge, MA, 3Janssen Research & Development, LLC, Titusville, NJ, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Cedars-Sinai Medical Center, Los Angeles, CA, 6University Hospital Paris-Saclay, Le Kremlin Bicêtre, France

    Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…
  • Abstract Number: 1546 • ACR Convergence 2022

    Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry

    Sebastian Sattui1, Zihan Wan2, Fenglong Xie2, Cassie Clinton2, Robyn Domsic1 and Jeffrey Curtis3, 1University of Pittsburgh, Pittsburgh, PA, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Polymyalgia rheumatica (PMR) is one of the most common systemic rheumatic diseases in older adults. Glucocorticoids (GC) remain the main treatment, and although recommendations…
  • Abstract Number: 2118 • ACR Convergence 2022

    Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

    Jessica Walsh1, Laura Coates2, Philip J Mease3, Joseph Merola4, Peter Nash5, Alexis Ogdie6, William Tillett7, Paolo Gisondi8, Barbara Ink9, Deepak Assudani9, Rajan Bajracharya9, Jérémy Lambert10, Vanessa Taieb11, Damon Willems12 and Lars Erik13, 1University of Utah, Salt Lake City, UT, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5School of Medicine, Griffith University, Sunshine Coast, Australia, 6Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 7Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 8Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Colombes, France, Irigny, France, 11UCB Pharma, Colombes, France, 12UCB Pharma, Brussels, Belgium, 13Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark

    Background/Purpose: Examine the association between achieving increasingly stringent clinical disease control criteria and patient-centric measures of physical function and pain in patients with PsA, using…
  • Abstract Number: 2142 • ACR Convergence 2022

    Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial

    William Tillett1, Laura Coates2, Mohamed Sharaf3, Marlies Neuhold4, Elke Theander5, Paul Bergmans6, May Shawi7, Michelle Perate8, Christine Contré9 and Philip Helliwell10, 1Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, 5Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, 6Formerly at Janssen, Breda, Netherlands, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Janssen Scientific Affairs, LLC, Horsham, PA, 9Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, 10Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Accurate assessment of psoriatic arthritis (PsA) disease activity in clinical practice requires a feasible, continuous, multidimensional composite instrument to assess key domains of this…
  • Abstract Number: 2127 • ACR Convergence 2022

    Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years

    Laura Coates1, Laure Gossec2, Christine Contré3, May Shawi4, Emmanouil Rampakakis5, Natalie Shiff6, Alexa Kollmeier7, Xie L Xu8, Peter Nash9, Philip J Mease10 and Philip Helliwell11, 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 2Sorbonne Université, Paris, France, 3Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, 4Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 5McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 6Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, 7Janssen-Cilag, Research & Development, LLC, San Diego, CA, 8Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, 9School of Medicine, Griffith University, Sunshine Coast, Australia, 10Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 11Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Recent guidelines from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommend that psoriatic arthritis (PsA) therapy achieve lowest possible…
  • Abstract Number: 2095 • ACR Convergence 2022

    Validation Analysis of the Physician Global Assessment (PGA) Scale in Patients with Systemic Lupus Erythematosus Included in RELESSER-PROS Registry

    Laura Cáceres1, Iñigo Rúa-Figueroa1, Norman Jimenez2, María Galindo-Izquierdo3, Jaime Calvo4, Raul Menor Almagro5, Antonio Fernandez-Nebro6, Julia Martinez-Barrio7, Esther Rodriguez Almaraz3, Esther Uriarte Isacelaya8, Elena Aurrecoechea9, Natalia Mena Vazquez6, José Miguel Senabre10, José Antonio Bernal11, Ana Pérez12, Vicente Torrente13, F. Javier Narváez14, Clara Sangüesa15, Marta Arévalo16, Mercedes Freire17, Clara Moriano18, Carlota Iñiguez19, Eva Tomero Muriel20, José Luis Andreu21, Mª Jesús García22, Tatiana Cobo23, Gema Bonilla24, Nuria Lozano25, Loreto Horcada26, Carlos Montilla27, Lorena Expósito28, María Esther Ruiz29, José Eloy Oller30, Ángela Pecondón31, Javier Loricera32, Francisco Javier Novoa33, Eva Salgado34, Tarek Carlos Salman-Monte35, Alejandro Muñoz36, Jorge J Fragío Gil37 and Jose M Pego-Reigosa38, 1Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, 2IRIDIS Group, Vigo, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Hospital Universitario de Araba, Vitoria, Spain, 5Hospital Jerez de la Frontera, Cádiz, Spain, 6Regional University Hospital of Málaga, Málaga, Spain, 7Hospital General Universitario Gregorio Marañón, Madrid, Spain, 8Hospital Universitario Donostia, Donostia, Spain, 9Hospital de Sierrallana, Torrelavega, Spain, 10Hospital Marina Baixa, Villajoyosa, Spain, 11Hospital Marina Baixa (Villajoyosa), Alicante, Spain, 12University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, 13Hospital de Sant Joan Despí Moisès Broggi/Consorci Sanitari Integral (CSI), Sant Joan Despí, Spain, 14Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, 15Hospital Universitario Severo Ochoa, Madrid, Spain, 16Parc Tauli Hospital Universitari, Sabadell, Catalonia, Spain, 17Complejo H. Universitario de A Coruña, A Coruña, Spain, 18Complejo Asistencial Universitario de León, León, Spain, 19Hospital Universitario Lucus Augusti, Division of Rheumatology, Lugo, Spain, 20Hospital Universitario La Princesa, Madrid, Spain, 21Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 22Hospital Universitario Ramón y Cajal, Madrid, Spain, 23Hospital Infanta Sofía, San Sebastián de los Reyes, Spain, 24Hospital Universitario La Paz, Madrid, Spain, 25Hospital Virgen de la Arrixaca, Murcia, Spain, 26Complejo Hospitalario de Navarra, Pamplona, Spain, 27Complejo asistencial Universitario de Salamanca, Salamanca, Spain, 28Hospital Universitario de Canarias, La Laguna, Spain, 29Hospital Universitario de Basurto, Bilbao, Spain, 30Hospital Universitario Dr. Peset, València, Spain, 31Hospital Universitario Miguel Servet, Zaragoza, Spain, 32Hospital Universitario Marqués de Valdecilla, Santander, Spain, 33Complejo Hospitalario Universitario Insular de Gran Canarias, Las Palmas de Gran Canaria, Spain, 34Complejo Hospitalario De Orense, Ourense, Spain, 35Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, 36Hospital Universitario Virgen del Rocío, Sevilla, Spain, 37Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, 38Hospital Meixoeiro, Vigo, Spain

    Background/Purpose: There is currently no agreement on which scale should be used to evaluate SLE disease activity. The aim of this study was to analyze…
  • Abstract Number: 2037 • ACR Convergence 2022

    Childhood-onset Sjögren’s Syndrome Is Characterised by Dysregulated of B and T Memory Cell Frequencies: A Pilot Immunophenotyping Analysis of This Rare Disease Phenotype

    Lucia Martin-Gutierrez1, Hannah Peckham2, Anna Radziszewska2, Junjie Peng2, Oluwatomisin Nettey2, Elizabeth Jury3 and Coziana Ciurtin4, 1Centre for Rheumatology Research, Department of Medicine,University College London, London, 2Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, 3University College London, London, United Kingdom, 4Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, United Kingdom

    Background/Purpose: Sjögren's syndrome (SS) is an autoimmune rheumatic disease characterised by dryness resulting from chronic lymphocytic infiltration of the exocrine glands and extra glandular manifestations…
  • Abstract Number: 2039 • ACR Convergence 2022

    The Tubarial Glands Resemble the Palatal Salivary Glands Based on Further Histological Characterization, and May Represent an Organ of Interest in Primary Sjögren’s Syndrome

    Sarah Pringle1, Floris Bikker2, Wouter Vogel3, Ingrid Hofland3, Bert van der Vegt4, Hendrika Bootsma1, Frans Kroese1, Arjan Vissink5 and Matthijs Valstar3, 1University Medical Center Groningen, Groningen, Netherlands, 2ACTA, Amsterdam, Netherlands, 3NKI, Amsterdam, Netherlands, 4University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 5UMCG, Leek, Netherlands

    Background/Purpose: Primary Sjögren's syndrome (pSS) often results in dysfunction of the salivary glands (hyposalivation and xerostomia) and substantial decrease in patient quality of life. High…
  • « Previous Page
  • 1
  • …
  • 425
  • 426
  • 427
  • 428
  • 429
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology